Diversified Trust Co. Sells 9,560 Shares of Cencora, Inc. $COR

Diversified Trust Co. reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 22.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,236 shares of the company’s stock after selling 9,560 shares during the period. Diversified Trust Co.’s holdings in Cencora were worth $11,225,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. IAG Wealth Partners LLC purchased a new stake in Cencora in the 3rd quarter worth approximately $30,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares in the last quarter. Cloud Capital Management LLC bought a new position in shares of Cencora in the third quarter worth approximately $31,000. Caitlin John LLC bought a new position in shares of Cencora in the third quarter worth approximately $31,000. Finally, Westside Investment Management Inc. increased its stake in shares of Cencora by 200.0% in the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after purchasing an additional 70 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on COR. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Evercore reissued an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Morgan Stanley set a $380.00 price objective on Cencora in a research note on Tuesday, March 17th. Twelve analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average price target of $403.17.

Insider Activity

In related news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.38% of the company’s stock.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora agreed to buy the retina business of EyeSouth Partners for about $1.1 billion, expanding its Retina Consultants of America platform and adding specialized ophthalmology services that can drive higher-margin, recurring revenue and cross‑sell opportunities within its clinical and distribution businesses. Cencora to buy retina business of EyeSouth Partners for $1.1 billion — Reuters
• Neutral Sentiment: Cencora is included in actively managed ETF lineups (mentioned in a MarketBeat piece on active ETFs), which could modestly support demand from funds that favor active strategies but is unlikely to materially change near‑term fundamentals. Active ETFs Surge Past Passive, and These Are in the Lead — MarketBeat
• Neutral Sentiment: Multiple industry outlets and deal roundups covered the EyeSouth sale and other sector M&A activity — reinforcing that consolidation in specialty care remains active but not necessarily changing Cencora’s near‑term revenue guidance. Olympus Partners to sell EyeSouth’s retina business for $1.1b — PEHub
• Negative Sentiment: CFO retirement and a planned leadership change this summer raise questions about near‑term capital allocation and execution on growth plans; combined with the $1.1B deal, investors may be concerned about leverage and integration risk given Cencora’s relatively high debt levels. Cencora CFO Retirement Puts Capital Allocation And Growth Plans In Focus — Yahoo Finance

Cencora Price Performance

Shares of NYSE:COR opened at $320.68 on Tuesday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a fifty day moving average price of $354.50 and a 200 day moving average price of $340.44. Cencora, Inc. has a fifty-two week low of $265.59 and a fifty-two week high of $377.54. The firm has a market cap of $62.38 billion, a price-to-earnings ratio of 38.54, a P/E/G ratio of 1.52 and a beta of 0.68.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.73 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s payout ratio is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.